IMS 2022 | IMS session highlights: high-risk myeloma
Wee Joo Chng
• 26 Sep 2022
Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, shares his highlights from the high-risk myeloma session that was held at this year’s IMS meeting. Prof. Chng mentions the identification of new signatures related to high-risk disease, as well as the need to detect small high-risk clones that may later impact patient outcomes, and highlights the efficacy of quadruplet induction therapy in this patient population. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
